Reserved area

Credentials and contents in the EryDel “RESERVED AREA” are strictly confidential and the access is authorized only for the medical staff operating the EDS in the ATTeST study. The Content of the “RESERVED AREA” should not be copied, distributed or reproduced in whole or in part, nor distributed to any third party if not for the  training purpose of authorized EDS Operators. The Content of the “RESERVED AREA” is only for medically trained staff.

I Agree


EryDel Appoints Guenter R Janhofer, MD, as Chief Medical Officer
Urbino, Italy – February 16, 2018 - EryDel SpA (, a clinical stage biopharmaceutical company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced the appointment of Guenter Reinhold Janhofer, MD, to the position of Chief Medical Officer

» Download Press Release

Where We Are